title: A phase II study of crisnatol mesylate in patients with ovarian carcinoma.
abstract: Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate, administered intravenously. There was no evidence of antitumor efficacy. A syndrome of nausea and vomiting associated with vertigo, dizziness and ataxia was observed in nearly all patients. Two of the patients developed severe CNS toxicity manifested in one by a grand-mal seizure and in the other by peripheral neuropathy. Further explorations into the potential efficacy of crisnatol mesylate administered intraperitoneally are underway.
authors.affiliation: Clinical Cancer Center, University of Wisconsin.
authors.forename: R V
authors.initials: RV
authors.lastname: Smalley
authors.forename: D
authors.initials: D
authors.lastname: Goldstein
authors.forename: D
authors.initials: D
authors.lastname: Bulkowski
authors.forename: C
authors.initials: C
authors.lastname: Hannon
authors.forename: D
authors.initials: D
authors.lastname: Buchler
authors.forename: C
authors.initials: C
authors.lastname: Knudsen
authors.forename: R L
authors.initials: RL
authors.lastname: Tuttle
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000187:drug effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D002911:Chrysenes / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011409:Propylene Glycols / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents; D002911:Chrysenes; D011409:Propylene Glycols; C056722:crisnatol